Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics Inc (ARQT)
:ARQT
Earnings Data
Report Date
Aug 13, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.42Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: -6.42%
|Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance by Arcutis with significant revenue growth and positive developments in their pipeline and market expansion. However, there are challenges related to increased SG&A expenses and typical first-quarter revenue declines. The overall sentiment is bolstered by the strategic management of IP and positive prescription trends despite seasonal challenges.Company Guidance
During Arcutis Biotherapeutics' Q1 2025 earnings call, the company reported robust financial performance with revenues of $63.8 million, nearly doubling year-over-year, despite a typical Q1 decline due to insurance deductible resets. Prescription demand grew by 10% compared to Q4 2024, reflecting strong commercial execution. The company highlighted significant growth opportunities, particularly through the anticipated approval of ZORYVE foam for scalp and body psoriasis on May 22, 2025, and ZORYVE cream for atopic dermatitis in young children by October 2025. Arcutis also addressed intellectual property protection efforts, noting a stay in litigation with Padagis. The firm maintained an 80% insurance coverage rate for ZORYVE prescriptions and expects to achieve cash breakeven by 2026, supported by its strong balance sheet and continued growth in the dermatology market.Record Revenue Growth
Arcutis reported first-quarter revenues of $63.8 million, reflecting a 196% growth year-over-year and nearly doubling revenues, excluding a previous non-recurring adjustment.
ZORYVE Demand Growth
Despite typical Q1 headwinds, ZORYVE prescription demand grew 10% compared to Q4 2024, demonstrating robust market presence.
Expansion in Insurance Coverage
Approximately 80% of ZORYVE prescriptions are reimbursed, reflecting strong insurance coverage across the portfolio.
Pipeline Progress
Anticipated upcoming approvals for ZORYVE foam for scalp and body psoriasis and ZORYVE cream for atopic dermatitis, demonstrating ongoing R&D advancements.
Intellectual Property Protection
Arcutis successfully extended the 30-month Hatch-Waxman stay by agreeing to stay patent litigation with Padagis, reinforcing their confidence in their patent portfolio.
ARQT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ARQT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $14.32 | $13.70 | -4.33% |
Feb 25, 2025 | $12.20 | $13.22 | +8.36% |
Nov 06, 2024 | $9.66 | $10.40 | +7.66% |
Aug 14, 2024 | $9.58 | $8.50 | -11.27% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Arcutis Biotherapeutics Inc (ARQT) report earnings?
Arcutis Biotherapeutics Inc (ARQT) is schdueled to report earning on Aug 13, 2025, TBA Not Confirmed.
What is Arcutis Biotherapeutics Inc (ARQT) earnings time?
Arcutis Biotherapeutics Inc (ARQT) earnings time is at Aug 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARQT EPS forecast?
ARQT EPS forecast for the fiscal quarter 2025 (Q2) is -0.17.